Reuters logo
3 months ago
BRIEF-Bluebird Bio, Celgene Corp announce updated clinical results from ongoing first-in-human multicenter study
June 5, 2017 / 11:41 AM / 3 months ago

BRIEF-Bluebird Bio, Celgene Corp announce updated clinical results from ongoing first-in-human multicenter study

June 5 (Reuters) - Celgene Corp:

* Bluebird Bio and Celgene Corporation announce updated clinical results from ongoing first-in-human multicenter study of bb2121 anti-bcma car t cell therapy in relapsed/refractory multiple myeloma at ASCO annual meeting

* Celgene Corp says 73% of evaluable patients in the trial active dose cohorts achieved a very good partial response

* All patients tested for minimal residual disease (MRD) status (n=4) were found to be MRD-negative

* Celgene Corp says no disease progression has been observed in active dose cohorts as of may 4, 2017 data cut-off Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below